TNGX

3.60

6.49% -0.25

Handel nachbörslich: 3.61 0.010 +0.28%

Tango Therapeutics Inc (TNGX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TNGX? Forum Prognose

Schlusskurs vom Vortag:

$3.85

Offen:

$3.82

24-Stunden-Volumen:

1.65M

Relative Volume:

0.97

Marktkapitalisierung:

$386.70M

Einnahmen:

$42.51M

Nettoeinkommen (Verlust:

$-116.49M

KGV:

-2.9752

EPS:

-1.21

Netto-Cashflow:

$-120.82M

1W Leistung:

+6.51%

1M Leistung:

-51.74%

6M Leistung:

-52.13%

1J Leistung:

-52.63%

1-Tages-Spanne:

$3.54

$3.84

1-Wochen-Bereich:

$3.255

$4.1391

52-Wochen-Spanne:

$2.70

$13.01

Tango Therapeutics Inc Stock (TNGX) Company Profile

Firmenname

Tango Therapeutics Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

(857) 320-4900

Adresse

201 BROOKLINE AVENUE, BOSTON

Mitarbeiter

140

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

TNGX's Discussions on Twitter

Vergleichen Sie TNGX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TNGX	3.60	386.70M	42.51M	-116.49M	-120.82M	-1.21
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-08	Eingeleitet	B. Riley Securities	Buy
2022-10-20	Hochstufung	H.C. Wainwright	Neutral → Buy
2021-09-20	Eingeleitet	SVB Leerink	Outperform

Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten

Nov 17, 2024

Trv Gp Iv LLC Has $129.82 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat

Nov 17, 2024

Nov 15, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from Analysts - MarketBeat

Nov 15, 2024

B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World

Nov 15, 2024

Nov 14, 2024

B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat

Nov 14, 2024

B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World

Nov 14, 2024

Nov 13, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com

Nov 13, 2024

Nov 12, 2024

Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 12, 2024

Nov 11, 2024

The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga

Nov 11, 2024

B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat

Nov 11, 2024

FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World

Nov 11, 2024

Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat

Nov 11, 2024

Nov 09, 2024

EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India

Nov 09, 2024

EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia

Nov 09, 2024

Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Tango Therapeutics sees $9.67m stock sale by Boxer Capital - Investing.com India

Nov 07, 2024

Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim - MarketBeat

Nov 07, 2024

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Nov 07, 2024

Nov 06, 2024

Two to Tango: Brain cancer drugs go further into development - BioWorld Online

Nov 06, 2024

Tango stock plunges 28% amid pipeline updates, Q3 earnings report (NASDAQ:TNGX) - Seeking Alpha

Nov 06, 2024

U.S. Stock market: Sunnova energy(-42.35%0, Zoomcar(-38.48%), Tango therapeutics(-27.22%) among stock losers during early trading - Business Upturn

Nov 06, 2024

Tango Shares Plunge After 3Q Loss, Product Plans - MarketWatch

Nov 06, 2024

Tango Therapeutics advances cancer drug into full development By Investing.com - Investing.com Canada

Nov 06, 2024